CONCLUSION
To our knowledge, this is the first case report about Dolutegravir causing acquired sideroblastic anemia. Even though Dolutegravir is a new antiretroviral drug with effective virologic suppression, good tolerability, infrequent drug-drug interactions, and once-daily administration, patients might be experiencing certain side effects like sideroblastic anemia. Early recognition and prompt management of such issues is a must since it might impact drug compliance and ultimately the quality of life. The majority of individuals with anemia who are treated in primary care clinics are thought to have iron deficiency anemia, which is more frequent. Clinicians must, however, be aware of the potential for sideroblastic anemia. To properly manage the patient, the primary care physician, nurse practitioner, and internist must be able to identify and diagnose this illness. To assess the prognosis and epidemiology of this condition, more clinical research is also required.